Pfizer
New York, NY, USA
WHY PATIENTS NEED YOU Hympavzi (marstacimab) is a human monoclonal antibody that promotes clotting activity in patients with Hemophilia A or B by targeting an endogenous anticoagulant protein called tissue factor pathway inhibitor (TFPI). The current standard of care in Hemophilia treatment is factor intravenous infusion (in Hem A and in Hem B) or subcutaneous injection emicizumab (in Hem A only). With a novel mechanism of action, differentiated clinical outcomes, and unique dosing and administration, Hympavzi is a breakthrough in hemophilia treatment. Hympavzi is a critical launch asset with accountability to contribute to near term growth and is important to delivering on Pfizer’s purpose of developing Breakthroughs that change patient’s lives. The hemophilia landscape is poised for disruption with several new molecules either recently launched and/or imminently launching in the next couple of years. As a combined $17B market, this represents one of the...